Chemours co president Michael Foley buys $29,999 in stock
Chemours insider Michael Robert Foley, president of Titanium Technologies, bought 1,934.2313 shares of Chemours (NYSE:CC) on Aug. 7, 2026 for about $29,999 at $15.51 to $15.54 per share. The purchase follows Q2 2026 results of $0.42 EPS on $1.59B revenue, below estimates, and a UBS downgrade to Neutral with a $18 target.
How this was made
The 30-second read
Why it matters
For traders, the insider buy is incremental, while the earnings miss and downgrade provide the clearer fundamental risk framing for CC’s refrigerant segment.
Market read
Insider buying is noted, but the actionable narrative is Chemours’ recent earnings miss and UBS concerns about refrigerant market share and destocking.
What to watch
The article’s most decision-relevant items are the earnings miss and UBS downgrade thesis on refrigerants, not the magnitude of the insider transaction.
Background
The piece centers on an insider stock purchase at The Chemours Company, then references recent earnings and a UBS downgrade.
Ticker impact
Chemours president Michael Foley bought 1,934 shares on Aug 7 at about $15.51 to $15.54, totaling $29,999.
Likely limited near-term impact from the small buy; the more tradable signal is the UBS downgrade tied to refrigerant weakness.
Insider purchases can be sentiment-positive, but the dollar amount is small and the text’s larger fundamental catalysts are the earnings miss and the downgrade.
Market effects
Highlights ongoing scrutiny of refrigerant demand and destocking dynamics in specialty chemicals.
No specific regional impact described.
No explicit global macro or cross-border catalyst described.
Counterpoint
The insider buy is small and may reflect routine compensation or diversification rather than a strong forward view.
Key entities
- companyThe Chemours Company
Subject of the insider purchase and referenced earnings/downgrade.
- personMichael Foley
Chemours president (Titanium Technologies) who purchased shares.
- institutionUBS
Downgraded Chemours from Buy to Neutral and cut its price target.
